Biopsy Guidance System Market Booming Worldwide Opportunity, Competitive Analysis, Future Prospects 2032 | FMI

 The global Biopsy Guidance System Market is anticipated to create an opulent growth outlook of the market over the assessment period by registering a CAGR of 5.8% from 2022 to 2032. The global market was valued at US$ 1.1 Billion in 2021 and is expected to surpass a valuation of US$ 2 Billion by 2032.

The market for Stereotactic Guided Biopsy is expected to be the highest revenue-generating segment expected to grow at a CAGR of 6.1% from 2022 to 2032. According to the historical analysis conducted by Future Market Insights, a market research and competitive intelligence provider, the global biopsy guidance system market registered a CAGR of 5.1% from 2017 to 2021.  

Get Full Access @ https://www.futuremarketinsights.com/reports/biopsy-guidance-system-market

Due to the rising prevalence of cancer, the surge in the geriatric population, increasing demand for non-invasive procedures, technological innovations, and government initiatives are the key drivers for the market. A biopsy is one of the most common procedures for diagnosing cancer and other chronic diseases, and it is used to diagnose breast, brain, skin, and prostate cancers. Furthermore, the demand for non-invasive procedures is skyrocketing owing to the boost in demand for biopsy guidance systems, resulting in a surge in the need for biopsy guidance systems. Patients recover faster and are less traumatized as a result of these procedures.  

A significant surge has been witnessed in the incidences of cancer which is one of the primary factors driving the market expansion. Because the biopsy guidance system is one of the most important requirements for the initial diagnosis of cancer, the market is expected to grow at a rapid pace over the forecast period. In addition to that, a substantial increase in the incidence of cancer, more advanced technology, safer, and more effective biopsies are being developed, which is driving the biopsy market. Non-invasive procedures are becoming more popular, which is fueling market growth in that area.

Report Highlights

With the substantial increase in the incidence of cancer along with rising technological advancements, safer and more effective biopsies are rapidly being developed, which is driving the biopsy market globally. Non-invasive procedures are becoming more popular, which is fueling market growth in that area.

Patients attributed to the high costs and painful side effects associated with this treatment have resulted in undiagnosed or inadequate diseases later in life, often avoiding invasive biopsies. These symptoms consequently increase mortality rates and lead to greater expenses and difficulties in treatment.

Recent Developments

When the tumor is located deep inside the body, image-guided biopsies are employed. The Biopsy guidance systems are known as both cost-effective and simple to operate. They can provide superb real-time details that cause the procedure to be less uncomfortable and more efficient for the patient. Furthermore, these guided biopsies can enable to rapid inspect numerous lesions in the axillary and sub-areolar areas.

The robotic biopsies segment is on the rise due to its less invasive nature. A rising number of product launches, combined with quick FDA approval, are also contributing to the segment's growth.

Increased awareness of Tissue Sampling Technology along with surging healthcare infrastructure development, impressive reimbursement policies, increased investment in healthcare research and development, and an upsurge in the number of hospitals and diagnostic centers are expected to drive demand for biopsy guidance systems during the assessment period.

Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16226

Competitive Landscape

With several local firms vying against multinational competitors, the market is significantly fragmented. To stay competitive in the industry, major businesses are focusing more on research and development of new products.

 The prominent players in the Biopsy Guidance System Market are Becton, Dickinson, and Company, Hologic, Inc., Devicor Medical Products, Inc., B. Braun Melsungen AG, and ARGON MEDICAL. Major market players use a variety of methods to preserve their dominance, including high Research and Development activity, global expansion strategies, broad product offers, and frequent introduction of advanced versions of existing items.

Market Segments Covered in Biopsy Guidance System Market Analysis

By Product Type:

  • Stereotactic Guided Biopsy
  • Ultrasound Guided Biopsy
  • MRI Guided Biopsy

By Application:

  • Brain Biopsy
  • Breast Biopsy
  • Other Applications

By End-User:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centres
  • Research and Academic Institutes

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more